A recent study has highlighted the role of HMGB1 as a potential mediator in the development of postoperative delirium.
News and events
In literature has been demonstrates that HMGB1 induces cell migration by activating RAGE or CXCR4 receptor through a heterologous complex with CXCL12.
A recent study in the journal Frontiers underscores the association between HMGB1 and autophagy in the progression and complications of diabetes mellitus.
HMGB1, proinflammatory mediator belonging to the alarmin family, is making waves in asthma research.
During tissue inflamation, HMGB1 protein is secreted by various immune cells and has a dual way of entering the extracellular space.
HMGBiotech has joined the conference “Goodbye Flat Biology: Next Generation Cancer Models” promoted by EACR, through a poster presentation by Dr. Andrea Lamarca.
A recent research has highlighted a groundbreaking discovery concerning the connection between HMGB1 released by mesothelial cells and the development of asbestos-induced mesothelioma.
Liam Colley, HMGBiotech’s researcher, gave a speech about “The role of CXCR4 in Triggering Immunosurveillance in the Malignant Mesothelioma Tumor Environment”.
HMGB1 has been shown to play a key role in Parkinson’s disease pathogenesis. Research and studies targeting High Mobility Group Box 1 (HMGB1) protein in Parkinson’s disease (PD) has recently emerged, with promising results in the inhibition of HMGB1.
Recent studies showed HMGB1’s role in the fight against cancer. HMGB1 is increasingly associated with tumor stages, prognosis, immune response and drug resistance.
Latest researches showed that HMGB1 is involved in causing ischemic stroke by ehnancing inflammation and tissue damage in cerebrovascular diseases.